Should I Buy FEMY? FEMY 2026 Analysis

Should You Buy Femasys Inc (FEMY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.510

1 Day change

4.74%

52 Week Range

1.800

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the trend remains bearish (SMA_200 > SMA_20 > SMA_5) and momentum is still negative (MACD histogram below 0).
Price (~0.54 post-market) is trading below the pivot (0.579) and closer to support (0.52), suggesting the stock is still in a weak technical posture despite a modest recent bounce.
The Switzerland expansion news is constructive, but fundamentals still show rising losses and margin pressure; without a clear technical reversal or proprietary buy signal, risk/reward is not attractive for an impatient entry.
Net: HOLD / avoid new buying until price reclaims the 0.579–0.637 zone with improving momentum.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating the broader downtrend is still intact.
Momentum: MACD histogram is negative (-0.00402) and only “negatively contracting,” which hints selling pressure may be easing but has not flipped bullish.
RSI (6): 35.5, near the lower range (weak/near-oversold behavior), which can allow short bounces but is not a buy signal by itself.
Key levels: Support S1 = 0.52 (then S2 = 0.484); Resistance/Pivot = 0.579; Upside resistances R1 = 0.637, R2 = 0.674.
Practical read: At ~0.54, the stock is still below pivot resistance; a failure to hold 0.52 increases downside risk toward ~0.484, while a reclaim of 0.579 improves odds of a move toward 0.637.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

Partnership with OR Consulting to launch FemBloc and FemaSeed in Switzerland supports European expansion and potential commercialization momentum.

Neutral/Negative Catalysts

- Ongoing losses and deteriorating profitability: 2025/Q3 net income fell to -4.19M (worse YoY), EPS down to -0.10 (down YoY), and gross margin decreased to 47.97%.
- Technical setup is still bearish (moving averages stacked bearishly; MACD still below zero), making upside follow-through less reliable.
- Hedge funds and insiders show no meaningful recent accumulation signal (both neutral), reducing confirmation from “smart money” flows.
- Pattern-based forward odds provided are slightly negative over 1 month (-1.59%), implying weak near-term drift.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 729,394 (+31.44% YoY) — positive growth trend.
Profitability: Net income -4,194,821 (down -22.45% YoY) — losses widened.
EPS: -0.10 (down -58.33% YoY) — per-share performance deteriorated.
Gross margin: 47.97% (down -7.50% YoY) — margin compression is a negative quality signal.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

(2025-11-20) Laidlaw initiated coverage: Buy rating, $6.50 price target.
Recent trend in ratings/targets: only one initiation is provided; no subsequent upgrades/downgrades or PT revisions are shown in the dataset.
Wall Street pro view (from provided data): Pros — large-market narrative around FemaSeed and clinical pathway for FemBloc, plus a bullish PT; Cons — still development-stage with weak earnings profile and ongoing losses, so the bullish thesis is catalyst-dependent.
Influential/political trading: No recent congress trading data available; hedge funds and insiders reported as neutral.

2 Analyst Rating

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 4.75 USD with a low forecast of 3 USD and a high forecast of 6.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.485

Low

Averages

4.75

High

6.5

Current: 0.485

Low

Averages

4.75

High

6.5

Laidlaw

Yale Jen

initiated

$6.50

AI Analysis

2025-11-20

Reason

Laidlaw

Yale Jen

Price Target

$6.50

AI Analysis

2025-11-20

initiated

Reason

Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.

JonesResearch

Buy

downgrade

$10 -> $6

2025-05-13

Reason

JonesResearch

Price Target

$10 -> $6

2025-05-13

downgrade

Buy

Reason

JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FEMY

Unlock Now

FEMY Should I Buy

FEMY Should I Buy

Should You Buy Femasys Inc (FEMY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch